Premium
Relaxin/RXFP1 Signaling in Prostate Cancer Progression
Author(s) -
Feng Shu,
Agoulnik Irina U.,
Li Zhen,
Han Hee Dong,
LopezBerestein Gabriel,
Sood Anil,
Ittmann Michael M.,
Agoulnik Alexander I.
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2008.03793.x
Subject(s) - relaxin , lncap , prostate cancer , tramp , cancer research , metastasis , prostate , cell growth , tumor progression , medicine , endocrinology , biology , cancer , receptor , genetics
We found that relaxin peptide expression is significantly elevated in recurrent human prostate cancer. Stimulation with relaxin increased migration, invasiveness, proliferation, and adhesion of LNCaP and PC3 cells in vitro . Opposite effects on cellular phenotype were observed after suppression of endogenous relaxin/RXFP1 expression or signaling. We showed an accelerated progression of prostate cancer in TRAMP males with transgenic relaxin overexpression and a longer survival of TRAMP, RXFP1‐deficient males. Suppression of RXFP1 expression in PC3 xenografts in nude mice by intratumoral injections of short interfering RNA resulted in decreased tumor size, cell proliferation, and metastasis rate.